Tumour necrosis factor (cachectin) induces phospholipase A2 activity and synthesis of a phospholipase A2-activating protein in endothelial cells
M.A. Clark, M.J. Chen, S.T. Crooke and J.S. Bomalaski
Biochemical Journal (1988), Vol. 250 pages 125-132
- Home
-
Company Info
- Management Team
- Bor-Wen Wu, PhD MBA
- John Bomalaski, MD
- Archie Prestayko, PhD
- W. Jenny Kung, PhD
- Wei He, PhD
- Jim Thomson, PhD
- Steve Wu
- Advisory Board
- Lloyd J. Old, MD
- Steven A. Curley, MD
- George Demetri, MD
- Robert C. Jackson, PhD
- Hsing-Jien Kung, MD PhD
- Jedd D. Wolchok, MD PhD
- Subsidiaries
- Polaris Pharmaceuticals
- TDW Pharmaceuticals
- DRX Pharmaceuticals
- DRX (Shanghai)
- Pipeline
- Collaborations
- Literature
- Company News
- Contact
- Literature
- Polaris & Collaborators
- ADI-PEG 20 (oncology)
- Uricase-PEG 20:
- TNF-PEG 20:
- CK2 inhibitor:
- ADI-PEG 20 (antiviral):
- Related Publications
- ADI general:
- ADI (oncology) renal cell carcinoma:
- ADI (oncology) combination therapy:
- TNF cancer treatment:
- CK2 inhibitor:
- Histidase cancer treatment:
© Copyright The Polaris Group. All rights reserved.